<DOC>
	<DOCNO>NCT01750190</DOCNO>
	<brief_summary>The purpose study determine whether FG-4592 safe effective treatment anemia chronic kidney disease patient dialysis .</brief_summary>
	<brief_title>A Study FG-4592 Treatment Anemia Chronic Kidney Disease Patients Not Receiving Dialysis</brief_title>
	<detailed_description>There screen period 6 week , variable treatment period individual subject minimum treatment duration 52 week maximum treatment duration time enroll subject plus 52 week last subject randomize , post-treatment follow-up period 4 week . A total 600 patient randomize 2:1 ratio receive either roxadustat ( FG-4592-approximately 400 subject ) placebo ( approximately 200 subject ) double-blind manner .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Chronic kidney disease , Stage 3 , 4 , 5 , receive dialysis Anemia qualify measurement hemoglobin value screen Additional blood work must safe range study entry Body weight 45 160 kg Willingness use contraception childbearing potential Treatment erythropoiesisstimulating agent ( ESA ) within 12 week prior study participation More one dose intravenous iron within 12 week prior study participation Blood transfusion within 8 week prior study participation Active infection Chronic liver disease Severe congestive heart failure , recent heart attack , stroke , seizure , blood clot Uncontrolled blood pressure within 2 week prior study participation Renal cell carcinoma History malignancy , include multiple myeloma myelodysplastic syndrome Chronic inflammatory disease could impact red blood cell production Any prior organ transplant , schedule organ transplantation Anticipated elective surgery expect lead significant blood loss , anticipate elective heart procedure Gastrointestinal bleeding Any prior treatment FG4592 HIFPHI Recent use investigational drug treatment , participation investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease ( CKD )</keyword>
	<keyword>non-dialysis</keyword>
	<keyword>Hemoglobin ( Hb )</keyword>
	<keyword>End-Stage Renal Disease</keyword>
	<keyword>erythropoeitin</keyword>
	<keyword>ASP1517</keyword>
	<keyword>erythropoeisis stimulating-agent</keyword>
	<keyword>AZD9941</keyword>
</DOC>